tbuckley/cabot-search huggingface dataset:
PWE-136 The Effect of C282Y Homozygosity on Full Blood Count Indices
Authors: S Hazeldine, M Van Rijnsoever, P Bentley, J Olynyk
Journal: Gut (2013)

<h3>Introduction</h3> Full blood count (FBC) indices and iron studies are utilised in initial screening of patients with clinical suspicion of haemachromatosis and HFE genetic testing is used for diagnosis. The aim of this study is to determine what effect haemachromatosis has on FBC indices and to detect any correlation with iron overload in subjects with C282Y homozygosity. <h3>Methods</h3> Data were obtained from blood samples taken from first time donors to the Australian Red Cross Service prior to venesection. FBC indices were recorded from C282Y homozygous patients and also from an age-matched healthy control group. Ferritin levels from the haemachromatosis group were also obtained. All P values were derived from two-tailed statistical tests and Chi-square tests. <i>P</i> values of less than 0.05 considered significant. Multivariate regression analysis was used to assess the differences between blood donors and haemachromatosis patients. <h3>Results</h3> The HFE group and normal controls were well matched with forty males and forty females in each group and no significant difference in age between the groups. Males homozygous for C282Y had a significantly (P = 0.001) higher mean ferritin level 787.3 mcg/L (522.1–1052.6) compared with females 268.3 mcg/L (147.1–389.4). Eighty percent of C282Y homozygous males presented with iron overload on their first Red Cross Blood donation visit, whereas only fifty percent of C282Y homozygous females had an elevated ferritin level on their first visit (P = 0.045). Of the forty patients homozygous for the C282Y mutations, there was evidence of iron overload in 26 patients (as defined by a ferritin greater than 200 mcg/L). There was no significant difference in all measure parameters between haemachromatosis patients with a ferritin lower than 200 mcg/L and healthy blood donors. Haemachromatosis patients with a ferritin level above 200 mcg/L (n = 26) had significant increases in haemoglobin (Hb) (P &lt; 0.001), mean cell volume (MCV) (P &lt; 0.026), mean corpuscular haemoglobin (MCH) (P &lt; 0.001) and mean corpuscular haemoglobin concentration (MCHC) (P &lt; 0.002). <h3>Conclusion</h3> Patients with C282Y homozygous haemachromatosis had a significantly higher Hb, MCV, MCH and MCHC. There is a clear correlation between ferritin and these raised red cell indices. A ferritin greater than 200 mcg/L is associated with a significant increase these red cell indices. Further studies are required to determine whether this increase in red cell indices is reversible with therapeutic venesection. <h3>Disclosure of Interest</h3> None Declared.
INDEX OF MICROCIRCULATORY RESISTANCE AND INFARCT SIZE IN ACUTE MYOCARDIAL INFARCTION: A VALIDATION STUDY USING CARDIAC MAGNETIC RESONANCE IMAGING
Authors: Takayuki Onishi, Yuko Onishi, Isshi Kobayashi, Shigeo Umezawa, Akihiro Niwa
Journal: Journal of the American College of Cardiology (2016)
THE EFFECTS OF BETA-ADRENERGIC STIMULATION WITH ISOPROTERENOL AND THE CONTRIBUTION OF LEFT VENTRICULAR DIASTOLIC FUNCTION ON LEFT ATRIAL PRESSURE IN PATIENTS WITH ATRIAL FIBRILLATION: A COMPARISON TO ATRIAL PACING
Authors: Tae-Hoon Kim, Junbeom Park, Jin-Kyu Park, Jae-Sun Uhm, Boyoung Joung, Moon-Hyoung Lee, Hui-Nam Pak
Journal: Journal of the American College of Cardiology (2015)
Indium-111 Pentetreotide Lung Uptake in Infectious Lung Disease
Authors: MASSIMO CASTELLANI, EUGENIO RESCHINI, MASSIMO GASPARINI, PAOLO GERUNDINI
Journal: Clinical Nuclear Medicine (1999)

Bilateral diffuse lung uptake of In-111 pentetreotide (OCT) was observed during a whole-body scan performed in a 68-year-old woman with Cushing's syndrome and suspected ectopic adrenocorticotropic hormone secretion. A few days later, she was found to have bilateral bacterial pneumonia (of mixed anaerobic origin). Cushing's syndrome was finally proved to be of pituitary origin. The OCT lung uptake in pneumonia probably resulted from tracer binding by somatostatin receptors on the inflammatory leukocytes. Although the rapid wash-out from experimentally induced abscesses does not make OCT a suitable tracer for detecting acute infections, the images and data here reported suggest that infectious lung disease should be excluded before diagnosing lung involvement by neuroendocrine tumors.
A Serious Adverse Event after Successful Gene Therapy for X-Linked Severe Combined Immunodeficiency
Authors: Salima Hacein-Bey-Abina, Christof von Kalle, Manfred Schmidt, Françoise Le Deist, Nicolas Wulffraat, Elisabeth McIntyre, Isabelle Radford, Jean-Luc Villeval, Christopher C. Fraser, Marina Cavazzana-Calvo, Alain Fischer
Journal: New England Journal of Medicine (2003)

To the Editor: We recently reported (April 18 issue)1 the sustained correction of X-linked severe combined immunodeficiency disease by ex vivo, retrovirally mediated transfer of the γc gene into CD34+ cells in four of five patients with the disease. These results have since been confirmed in four additional patients with typical X-linked severe combined immunodeficiency. Of the first four successfully treated patients, three continue to do well up to 3.6 years after gene therapy, whereas a serious adverse event occurred in the fourth patient. At a routine checkup 30 months after gene therapy, lymphocytosis consisting of a monoclonal population . . .
Good reason to test for vitamin D deficiency
Authors: H. M. Rhein
Journal: BMJ (2012)

Unlike in sunny Sydney, there is good reason to test for vitamin D deficiency when you live in Scotland. Here, a third of the adult population is grossly deficient and symptomatic, with serum concentrations below 25 nmol/L.Knowledgeable general practitioners are therefore not overtesting, overdiagnosing, or overtreating when they look for symptomatic vitamin D deficiency, arrange blood tests, and help improve symptoms by prescribing or suggesting vitamin D supplements.
Assessing the Hemodynamic Severity of Acute Aortic Regurgitation Due to Infective Endocarditis
Authors: Tift Mann, Lambert McLaurin, William Grossman, Ernest Craige
Journal: New England Journal of Medicine (1975)

Nine patients who underwent aortic-valve replacement for acute aortic regurgitation due to infective endocarditis were studied for clinical features that may be useful in assessing the severity of this condition. The traditional physical signs of a wide pulse pressure were absent. As compared to a group of patients with chronic aortic regurgitation, the mean (plus or minus S.D.) pulse pressure (55 plus or minus 7 vs. 105 plus or minus 22 mm Hg), left ventricular end diastolic volume (146 plus or minus 28 vs. 264 plus or minus 64 ml per square meter) and stroke volume (89 plus or minus 22 vs. 163 plus or minus 57 ml per square meter) were significantly smaller in the acute group (P less than 0.01). Left ventricular pressure exceeded left atrial pressure in late diastole, causing premature closure of the mitral valve, and the degree of early closure reflected the increase in left ventricular end diastolic pressure. Premature closure of the mitral valve was demonstrated by echocardiography in all patients. Those with echocardiographic signs of very early mitral-valve closure have severely volume-overloaded ventricles and are candidates for early valve replacement.
Treating Myeloproliferation — On Target or Off?
Authors: Mary Armanios, Carol W. Greider
Journal: New England Journal of Medicine (2015)

The classic myeloproliferative neoplasms — essential thrombocythemia, polycythemia vera, and primary myelofibrosis — are clonal disorders marked by overproduction of mature blood cells.1 Disease often evolves over many decades, and affected patients have symptoms related to extramedullary hematopoiesis, a thrombotic tendency, and, rarely, leukemic transformation.1 Hematopoietic stem-cell transplantation is the only curative therapy, and treatments usually focus on controlling symptoms.In this issue of the Journal, two groups of investigators present the results of studies of imetelstat, an antisense oligonucleotide, in phase 2 trials involving patients with essential thrombocythemia and primary myelofibrosis. Baerlocher et al.,2 who conducted a multi-institutional trial . . .
Lipoprotein(a), Apolipoprotein(a) Phenotypes, and Nephropathy in NIDDM Patients
Authors: Harukuni Akita, Hitoshi Chiba, Masayuki Noritake, Yoshiya Katsura, Yasuyo Udo, Shibuya Hitoshi, Shu-Ping Hui, Yukihiro Takahashi, Hironori Nagasaka
Journal: Diabetes Care (1996)
Distinct genetic involvement of the TP53 gene in therapy-related leukemia and myelodysplasia with chromosomal losses of Nos 5 and/or 7 and its possible relationship to replication error phenotype
Authors: S Horiike, S Misawa, H Kaneko, Y Sasai, M Kobayashi, H Fujii, S Tanaka, M Yagita, T Abe, K Kashima, M Taniwaki
Journal: Leukemia (1999)
SAT0028 Strict Acr-Remission within 6 Months Predicts Sustained Long-Term Very Low Disease Activity in Actively Treated Rheumatoid Arthritis Patients, 5-Year Results of the Neo-Raco Trial
Authors: V. Rantalaiho, H. Kautiainen, M. Korpela, M. Leirisalo-Repo
Journal: Annals of the Rheumatic Diseases (2013)

<h3>Background</h3> Most patients with rheumatoid arthritis (RA) achieve remission, have marginal radiographic progression and sustain normal function when an initial aggressive combination treatment with three disease modifying antirheumatic drugs (DMARDs) and prednisolone is used, with or without early biologics [1,2]. <h3>Objectives</h3> To study whether the time of the first strict ACR remission correlates with the consequent long-term disease activity in early, aggressively treated RA patients. <h3>Methods</h3> A total of 99 patients with early (&lt; 1 year), DMARD-naïve, active RA were treated with a combination of methotrexate, sulfasalazine, hydroxychloroquine, and prednisolone, and randomized to blindly receive either infliximab or placebo infusions during the first 6 months. After 24 months, if the patient was in remission, the treatments could be tapered down, and, in the case of flare-up, increased, with strict ACR remission as a goal. Subgroups were generated according to the time of the first ACR remission: 1: within 3 months (n=31), 2: within 6 months (n=28), 3: within 18 months (n=15), 4: after 18 months or not at all (n=19), and the area under curve between 2-5 years for disease activity score applying 28 joints (DAS28-AUC<sub>2-5y</sub>) was studied. <h3>Results</h3> A total of 93 patients (94%) were followed up for 60 months. The mean (SD) DAS28-AUC<sub>2-5y</sub> was: 1.55 (0.59) in group 1; 1.53 (0.62) in group 2; 1.91 (0.55) in group 3; and 2.29 (1.04) in group 4 (age, sex, RF, DAS28 at baseline adjusted p=0.0032). <h3>Conclusions</h3> In early RA, targeted treatment with a combination of DMARDs and prednisolone produces excellent long-term outcomes in most patients, with the mean disease activity below the remission limit in all patients. However, strict remission within 6 months predicts the lowest sustained disease activity. <h3>Acknowledgements</h3> Leirisalo-Repo et al. Ann Rheum Dis 2012 Jun 30 [Epub ahead of print] Rantalaiho V et al. Ann Rheum Dis 2012;71(Suppl 3): 103. <h3>Disclosure of Interest</h3> None Declared
SAT0395 Thyroid Autoimmunity, Not Thyroid Hormone, was Associated with Arterial Stiffness in Euthyroid FM Female Patients.
Authors: J. H. Lee, G.-T. Kim, S.-H. Baek
Journal: Annals of the Rheumatic Diseases (2013)

<h3>Background</h3> Muscle symptoms are frequent in thyroid diseases, and it has been recognized that there are significant similarities between the clinical findings in FM and symptoms of thyroid dysfunction. Some recent reports have found clinical and biochemical features of muscle dysfunction even in subclinical hypothyroidism. Another study reported that FM patients had some problems in the production or utilization of thyroid hormones, and there was an association between thyroid autoimmunity and FM. <h3>Objectives</h3> we performed this study to evaluate the effect of thyroid hormone variation and in particular, the effect of 'high-normal' TSH with positive antithyroid antibodies on endothelial function in euthyroid FM patients, using pulse wave velocity(PWV), which assess endothelial function by measuring the status of large and small arteries in the lower extremity. <h3>Methods</h3> This study included 155 postmenopausal female FM patients (51.5±8.9 years) without any known cardiovascular diseases within a normal reference range of thyroid-stimulating hormone (TSH) levels (0.4–4.5mIU/ml). The clinical parameters including Fibromyalgia Impact questionnaire (FIQ), pain visual analogical scale (VAS) and tender point counts and immunologic tests including rheumatoid factor and antinuclear antibody were measured. Vascular function was assessed by brachial-ankle pulse wave velocity (baPWV), augmentation index and flow-mediated dilation (FMD). We evaluated the associations between arterial markers and serum TSH, free thyroxin, as well as serum thyroidperoxidase autoantibody. <h3>Results</h3> The baPWV values of positive TPO Ab and those with negative TPO Ab (1632.1±385.2 cm/sec vs. 1323.2±210.7 cm/sec, <i>P</i>=0.015) were significantly different. Mean levels of PWV and FMD did not increase linearly across increasing TSH quartiles. No associations were found between the remaining markers and levels of thyroid hormones, whereas thyroid antibodies were significantly associated with baPWV (r=0.337, p=0.007). Linear regression analysis revealed that the only significant predictors of baPWV were age, FIQ and presence of TPO Ab. No significant association was found between FMD and positive anti-TPO antibodies. <h3>Conclusions</h3> FM women with positive TPO antibodies have increased arterial stiffness compared to women with negative TPO antibodies. The combined thyroid autoimmunity in FM patients may need re-evaluation with respect to the effects on the vasculature. <h3>Disclosure of Interest</h3> None Declared
Are Health Insurers Denying Patients Quality Care?
Authors: F. Antoine
Journal: JNCI Journal of the National Cancer Institute (1989)

Journal Article Are Health Insurers Denying Patients Quality Care? Get access Florence Antoine Florence Antoine Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 81, Issue 23, 6 December 1989, Pages 1766–1768, https://doi.org/10.1093/jnci/81.23.1766 Published: 06 December 1989
Deep enteroscopy in patients with left ventricular assist devices: practical and technical considerations
Authors: G. Decker, E. Miller, S. Pasha, M. Harrison, J. Leighton
Journal: Endoscopy (2010)

A 73-year-old man with ischemic cardiomyopathy and a left ventricular assist device (LVAD; HeartMate II; Thoratec Inc., Pleasanton, California, USA) ([Fig. 1]) [1] presented with recurrent melena.
OP0021-PARE Patients Become Political - How to Support Patients' Involvement in Guideline Work Groups and the Joint Federal Committee of Physicians and Health Insurance Companies (G-BA)
Authors: C. Sander
Journal: Annals of the Rheumatic Diseases (2014)

<h3>Background</h3> For a long time, health care professionals and insurance companies alone knew what is best for the patient. But a change of mind-set in politics and in society at large led to the Statutory Health Insurance Modernisation Act in Germany in 2004. It states, that relevant organisations which represent the interests of patients and self-help groups of chronically ill and disabled people have to be involved in questions concerning health issues and health care. Patient representatives (PR) of the Deutsche Rheuma-Liga participate in guideline work and political bodies of the health care system. They start out as active and dedicated patients who want to bring the patient perspective to the table. However, many come from non-healthcare related professions and have to face professionals of the health care system and insurance companies. <h3>Objectives</h3> Full time staff from the Deutsche Rheuma-Liga supports and will support patients with rheumatic diseases in all aspects of their work as PRs in healthcare related political committees. <h3>Methods</h3> For members who are interested in working as PR or who already work as PR, the Deutsche Rheuma-Liga – developed a “work description” including a brief background information about the political structures, qualifications that are good to have, and necessary requirements to fulfil the task – holds introductory work-shops to prepare new representatives – holds meetings where representatives can exchange their experiences – supports representatives with literature research and information input – if possible, a staff member accompanies new representatives to their first meeting – is available for questions related to any part of the work – informs about training courses from other institutions, e.g. G-BA. <h3>Results</h3> Deutsche Rheuma-Liga supports PRs who participate in a number of different political committees and was able to win new people who want to influence the health care system in favour of the patients. However, new ways have to be found to include young people with rheumatic diseases who have less time for volunteer work. <h3>Disclosure of Interest</h3> None declared <h3>DOI</h3> 10.1136/annrheumdis-2014-eular.4387
TCTAP C-054 Balloon Crush the Protruding Everolimus-Eluting Stent for Isolated Coronary Stenosis at Side Branch Ostium
Authors: Yasuhiro Nakano, Arihide Okahara, Daigo Mine, Yasuaki Koga, Keiki Yoshida, Kenji Sadamatsu
Journal: Journal of the American College of Cardiology (2015)
Establishing global health cancer care partnerships across common ground: bridging nuclear security, equitable access, education, outreach, and mentorship
Authors: C Norman Coleman, Silvia C Formenti, Nelson Chao, Surbhi Grover, Danielle Rodin, Daniel G Petereit, Bhadrasain Vikram, David A Pistenmaa, Majid Mohiuddin, Tim R Williams, Nina Wendling, Lawrence Roth, Mary Gospodarowicz, D Jaffray
Journal: The Lancet Global Health (2016)

Background The projection that by 2025, about 75% of cancer cases will be in the developing world is recognised by the WHO and the International Atomic Energy Agency. Radiation treatment machines (Cobalt-60 and linear accelerators) are critical for curative and palliative care. With an estimated global shortage of 5000 treatment machines, even commissioning one per week would require a century to solve the current shortfall. Despite, or possibly because of, these alarming statistics, there has been little concerted effort to solve the cancer care problem which is believed by some to be too expensive and overwhelming.
A 24-month subgroup analysis of the effect of denosumab on bone mineral density in women with breast cancer undergoing aromatase inhibitor therapy.
Authors: GK Ellis, HG Bone, R Chlebowski, D Paul, S Spadafora, M Fan, D Kim
Journal: Cancer Research (2009)

Abstract Abstract #2106 Background: Accelerated bone loss and fracture risk are expected consequences of adjuvant aromatase inhibitor (AI) therapy. We previously showed that denosumab, a fully human monoclonal antibody that inhibits RANK ligand (RANKL), significantly increased bone mineral density (BMD) at the lumbar spine and at all measured skeletal sites at 12 months compared with placebo in women with breast cancer undergoing adjuvant AI therapy (Ellis et al, 2007 SABCS). In this analysis, we assessed covariates that may influence treatment effects on BMD at the lumbar spine, total hip, femoral neck, and 1/3 radius at 24 months.&amp;#x2028; Methods: Adult patients (pts) with hormone receptor-positive breast cancer, who had evidence of low bone mass and were receiving adjuvant AI therapy, were enrolled in this randomized, double-blind, placebo-controlled, phase 3 study. Pts were stratified according to length of previous AI therapy (≤ 6 vs &amp;gt; 6 months) and randomly assigned to receive, together with calcium and vitamin D, placebo (n=125) or denosumab 60 mg (n=127) subcutaneously every 6 months for 4 doses. Subgroup analysis was conducted using analysis of covariance and adjusted for treatment, stratification factor, baseline BMD value, densitometer type, and baseline BMD value-by-densitometer-type interaction.&amp;#x2028; Results: At 24 months, greater increases in BMD were seen at all measured skeletal sites (both trabecular and cortical bone) for denosumab compared with placebo, regardless of the subgroup (table). Adverse events (AEs) occurred at a similar rate in both groups (91% denosumab, 90% placebo).&amp;#x2028; Conclusion: In pts with breast cancer undergoing adjuvant AI therapy, twice-yearly denosumab treatment showed consistent increases in BMD across the skeleton at 24 months compared with placebo, regardless of subgroups.&amp;#x2028; &amp;#x2028; Citation Information: Cancer Res 2009;69(2 Suppl):Abstract nr 2106.
Prognostic implications of isolated tumour cells and micrometastasis in lymph nodes in non-adjuvant treated breast cancer patients.
Authors: D Park, R Kåresen, B Naume, T Sauer
Journal: Cancer Research (2009)

Abstract Abstract #205 Introduction : The status of axillary lymph nodes (ALNs) is the most powerful predictor of survival and has clinical implications for adjuvant treatment of breast cancer patients. Occult metastases in ALNs of patients initially staged as negative have been detected up to 40%, using the various methods with serial sectioning and/or immunohistochemical (IHC) staining. However, there is no consensus concerning the prognostic significance for occult metastases. The aim of this study was to estimate the prognostic value of isolated tumor cells (ITC, ≤0.2 mm) and micrometastases (MM, 0.2-2.0 mm) in invasive breast cancer.&amp;#x2028; Materials and Methods: The ALNs of 295 patients with axillary node-negative invasive breast cancer treated from 1995 to 1998 was evaluated with serial sectioning and cytokeratin IHC (a single section from each of 10 levels) and hematoxylin-eosin (one section from 3rd and 10th level). Disseminated tumor cell status in bone marrow was also known. Of 295 patients, 232 were offered no systemic adjuvant therapy. Patients were categorized by largest cluster size (≤0,2mm, 0.2-2.0mm), and then their survival rates, i.e. disease-free survival (DFS), distant disease-free survival (DDFS) and breast cancer specific survival (BCSS) were compared with those of node-negative patients. We also investigated the correlation between occult metastases in ALNs and bone marrow (BM).&amp;#x2028; Results: The median patient age was 59 years and the median tumour size was 1.5 cm. At a median observation time of 98 months (9-127 months), 33 patients had developed relapse,2 local and 31 systemic. 17 patients had died of breast cancer. Occult metastases were found in 92 of 295 patients (31%); ITC – 58% (53/92), MM -34% (31/92) and macrometastases (&amp;gt;2.0mm)- 8% (8/92). The cases with macrometastases were excluded from survival analysis. The results presented in the table below demonstrate significant prognostic impact of MM on BCSS, borderline significance on DFS and DDFS. This was not shown for ITC. No significant correlation was found between occult metastases in ALN and BM in both total patients (Χ2-test, p=0.680).&amp;#x2028; &amp;#x2028; Conclusions: Our observation of a prognostic impact of MM in non-adjuvant treated patients indicates that adjuvant therapy might be warranted in this group. Lack of a similar finding in patients with ITC questions the need of adjuvant therapy in this group. The lack of correlation between occult metastases in ALN and BM indicates different “homing” mechanisms for the two compartments. Citation Information: Cancer Res 2009;69(2 Suppl):Abstract nr 205.